Ono Pharmaceutical Co. Ltd.
OPHLY | OTC
$5.15
+$0.07 (+1.38%)
Sep 21, 2026, 3:50 PM ET · Market open
+1.38%
(1D)Rating
Updated: Sep 17, 2026Key Statistics
Market Data
Market Cap $7.26B
1D Range
5.11 5.15
52W Range
3.71 5.75
Valuation (TTM)
PE 14.39
PB 1.37
EV/EBITDA 7.09
Valuation (NTM)
Forward PE 15.62
Forward PEG -1.25
Price Target N/A
Cash Flow
FCF Yield 11.5%
SBC Adj. FCF Yield 11.5%
SBC Impact N/A
Margins
Gross Margin 73.6%
Operating Margin 22.1%
FCF Margin 25.8%
Growth (CAGR)
Revenue 3Y | 5Y 3.7% |
9.8%
Dil EPS 3Y | 5Y 17.6% |
26.0%
FCF 3Y | 5Y 10.3% |
22.8%
Returns
ROA 7.0%
ROE 9.1%
ROIC 8.5%
Financial Health
Net Cash
¥110.65B ($680.84M)
Current Ratio 3.28
Interest Coverage 31.37
Dividends
Div Yield 3.30%
Payout Ratio 0.3%
FCF Payout Ratio 28.5%
Loading financial charts...
Profile
A detailed description of the company is not yet available.
Latest News
21 days ago · businesswire.com
Ono Pharma Enters into a Drug Discovery Partnership with Aitia in Neurological DiseasesOSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”) today announced that it has entered into a drug discovery partnership agreement with Aitia, Inc. (Headquarters: Cambridge, Massachusetts, USA; CEO: Colin Hill; “Aitia”). Under the terms of the agreement, Aitia will utilize its REFS™ technology to build Gemini Digital Twins (GDTs) of neurological diseases and identify new therapeutic targets and bio.
Add to Watchlist
Select watchlists to add or remove OPHLY